eMedicine Specialties > Emergency Medicine > Rheumatology

Systemic Lupus Erythematosus

Author: Mark J Leber, MD, MPH, FACEP, Attending Physician and Faculty, Department of Emergency Medicine and Residency Program, Lincoln Medical and Mental Health Center
Coauthor(s): Viraj S Lakdawala, MD, Resident Physician, Department of Emergency Medicine, Lincoln Medical and Mental Health Center, Bronx, NY
Contributor Information and Disclosures

Updated: Oct 27, 2009

Introduction

Background

Systemic lupus erythematosus (SLE) is a multiorgan system autoimmune disease with numerous immunological and clinical manifestations. It is characterized by an autoantibody response to nuclear and cytoplasmic antigens. The disease mainly involves the skin, joints, kidneys, blood cells, and nervous system. Diagnosing and managing SLE in the emergency department can be very challenging if it is not considered in one's differential diagnosis. Also, the laboratory testing of SLE may be unavailable on an emergent basis.

Pathophysiology

Systemic lupus erythematosus (SLE) is a multifactorial disease involving genetic, environmental, and hormonal factors. Its precise pathogenesis is unclear. There is growing evidence in favor of a clearance deficiency of apoptotic cells as the core mechanism in the pathogenesis of SLE.1 Defective clearance of apoptotic cells causes secondary necrosis with release of intracellular content and inflammatory mediators. Macrophages respond and present self-antigens to T and B cells.1

Pathogenic autoantibodies are the primary cause of tissue damage in patients with lupus. The production of these antibodies arises by means of complex mechanisms involving every key facet of the immune system.2 The abnormal cellular and humoral response to the formation of these autoantibodies is modulated by genetic, environmental, and hormonal factors:

  • Genetic factors
    • Genes of the MHC HLA-A1, B8, and DR3 have been linked to lupus.
    • Genetic deficiency of complement factors C1q, C2, or C4
  • Environmental factors3
    • Occupational exposure - Silica, pesticides, mercury
    • Drugs - Many drugs have been implicated in drug-induced lupus.
    • Sunlight
  • Epstein-Barr virus (EBV) has also been identified as a possible factor in the development of lupus.3

Frequency

United States

In the United States, the annual incidence of systemic lupus erythematosus (SLE) averages 5.1 per 100,000 per year. The incidence of SLE in black women is approximately 4 times higher than in white women. SLE is more frequent in Asian women than in white women.4

The reported prevalence of SLE in the population is 52 cases per 100,000.5

The frequency of SLE could be increasing due to mild forms of the disease that are being recognized.

International

The highest prevalences of systemic lupus erythematosus (SLE) were reported in Italy, Spain, Martinique, and the UK Afro-Caribbean population.5 SLE is more common in women with West African ancestry who have emigrated from their home area, suggesting that there may be an environmental trigger as well as a genetic basis for their disease.

Mortality/Morbidity

The life expectancy of such patients has improved from an approximate 4-year survival rate of 50% in the 1950s to a 15-year survival rate of 80% today.6 A patient in whom SLE is diagnosed by age 20 years still has a 1 in 6 chance of dying within 15 years, most often from lupus or infection.7 After 35, the patient is more likely to die from myocardial infarction or stroke.7

Infectious diseases have emerged as one of the leading causes of morbidity and mortality, accounting for 29% of all deaths in these patients.8

Women with SLE between 35 and 44 years of age had a 52-fold higher risk of having a myocardial infarction than matched women from the Framingham cohort.9

Ten-year survival rates in other countries in Asia and Africa are significantly lower, ranging from 60-70%.10,11,12


Race

Black women have a higher rate of SLE than any other race, followed by Asians, then white women.5

In the United States, black women are 4 times more likely to have SLE than white women.5

Sex

For all ages, the female-to-male ratio is 7:1 and 11:1 during the childbearing years.13

Age

Onset of systemic lupus erythematosus (SLE) is usually after puberty, typically in the 20s and 30s.

Twenty percent of all cases of lupus are diagnosed during the first 2 decades of life.14

Clinical

History

The triad of fever, joint pain, and rash in a woman of childbearing age should suggest the diagnosis of systemic lupus erythematosus (SLE). These 3 symptoms are some of the most commonly found symptoms in patients presenting with SLE.15,16

The American College of Rheumatology last updated the diagnostic criteria for SLE in 1997. The most current criteria are listed below.17,18
 

Open table in new window

[ CLOSE WINDOW ]
Table
CriterionDefinition
1. Malar rashFixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
2. Discoid rashErythematous raised patches with adherent keratotic scaling and follicular plugging (Atrophic scarring may occur in older lesions)
3. PhotosensitivitySkin rash as a result of unusual reaction to sunlight, by patient history or physician observation
4. Oral ulcersOral or nasopharyngeal ulceration, usually painless, observed by a physician
5. ArthritisNonerosive arthritis involving ≥2 peripheral joints, characterized by tenderness, swelling, or effusion
6. Serositis(A) Pleuritis: Convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion
or
(B) Pericarditis: Documented by ECG or rub or evidence of pericardial effusion
7. Renal disorder(A) Persistent proteinuria >0.5 g/d or >3+ if quantitation not performed
or
(B) Cellular casts: May be red blood cell, hemoglobin, granular, tubular, or mixed
8. Neurologic disorder(A) Seizures: In the absence of offending drugs or known metabolic derangements (eg, uremia, ketoacidosis, electrolyte imbalance)
or
(B) Psychosis: In the absence of offending drugs or known metabolic derangements (eg, uremia, ketoacidosis, electrolyte imbalance)
9. Hematologic disorder(A) Hemolytic anemia: With reticulocytosis
or
(B) Leukopenia: <4000/mm3 total on ≥2 occasions
or
(C) Lymphopenia: <1500/mm3 on ≥2 occasions
or
(D) Thrombocytopenia: <100,000/mm3 in the absence of offending drugs
10. Immunologic disorder(A) Anti-DNA: Antibody to native DNA in abnormal titer
or
(B) Anti-Sm: Presence of antibody to Sm nuclear antigen
or
(C) Positive finding of antiphospholipid antibodies based on (1) an abnormal serum level of IgG or IgM anticardiolipin antibodies, (2) a positive test result for lupus anticoagulant using a standard method, or (3) a false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption tests
11. Antinuclear antibodyAn abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with drug-induced lupus syndrome
A person can be diagnosed with SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.
CriterionDefinition
1. Malar rashFixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
2. Discoid rashErythematous raised patches with adherent keratotic scaling and follicular plugging (Atrophic scarring may occur in older lesions)
3. PhotosensitivitySkin rash as a result of unusual reaction to sunlight, by patient history or physician observation
4. Oral ulcersOral or nasopharyngeal ulceration, usually painless, observed by a physician
5. ArthritisNonerosive arthritis involving ≥2 peripheral joints, characterized by tenderness, swelling, or effusion
6. Serositis(A) Pleuritis: Convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion
or
(B) Pericarditis: Documented by ECG or rub or evidence of pericardial effusion
7. Renal disorder(A) Persistent proteinuria >0.5 g/d or >3+ if quantitation not performed
or
(B) Cellular casts: May be red blood cell, hemoglobin, granular, tubular, or mixed
8. Neurologic disorder(A) Seizures: In the absence of offending drugs or known metabolic derangements (eg, uremia, ketoacidosis, electrolyte imbalance)
or
(B) Psychosis: In the absence of offending drugs or known metabolic derangements (eg, uremia, ketoacidosis, electrolyte imbalance)
9. Hematologic disorder(A) Hemolytic anemia: With reticulocytosis
or
(B) Leukopenia: <4000/mm3 total on ≥2 occasions
or
(C) Lymphopenia: <1500/mm3 on ≥2 occasions
or
(D) Thrombocytopenia: <100,000/mm3 in the absence of offending drugs
10. Immunologic disorder(A) Anti-DNA: Antibody to native DNA in abnormal titer
or
(B) Anti-Sm: Presence of antibody to Sm nuclear antigen
or
(C) Positive finding of antiphospholipid antibodies based on (1) an abnormal serum level of IgG or IgM anticardiolipin antibodies, (2) a positive test result for lupus anticoagulant using a standard method, or (3) a false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption tests
11. Antinuclear antibodyAn abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with drug-induced lupus syndrome
A person can be diagnosed with SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.

Physical

  • Fever is a challenging problem in systemic lupus erythematosus (SLE). It can be a manifestation of active lupus or a representation of infection, malignancy, or drug reaction. Lower-grade temperature is observed in patients on immunosuppressive agents.
    • Patients with fever need to have infectious causes ruled out — both viral and bacterial. Patients with SLE who are on immunosuppressive therapy are at a higher risk of death due to viruses (ie, herpes simplex virus [HSV], cytomegalovirus [CMV], varicella-zoster virus [VZV]) and should be treated accordingly if a viral illness is suspected.19
    • An infection can mimic a lupus flare and delays in diagnosis and institution of
      treatment result in increased mortality.20
  • Malar rash is a fixed erythema that spares the nasolabial folds. It is a butterfly rash that can be flat or raised over the cheeks and bridge of the nose. It also often involves the chin and ears.
The classic malar rash, also known as a butterfly...

The classic malar rash, also known as a butterfly rash, with distribution over the cheeks and nasal bridge. Note that the fixed erythema, sometimes with mild induration as seen here, characteristically spares the nasolabial folds.

[ CLOSE WINDOW ]
The classic malar rash, also known as a butterfly...

The classic malar rash, also known as a butterfly rash, with distribution over the cheeks and nasal bridge. Note that the fixed erythema, sometimes with mild induration as seen here, characteristically spares the nasolabial folds.

  • Discoid rash occurs in 20% of patients with SLE and can result in disfiguring scars. The discoid rash can present as erythematous patches with keratotic scaling over sun-exposed areas of the skin. Systemic manifestations of SLE may be absent.
  • Alopecia or loss of hair may occur.
  • Lupus should be considered in all patients who experience painless or painful oral or vaginal ulcers.
  • Gastrointestinal findings include vague abdominal discomfort, nausea, and diarrhea. Acute crampy abdominal pain, vomiting, and diarrhea may signify vasculitis of the intestine.
  • Joint findings
    • Tenderness, edema, and effusions accompany a polyarthritis that is symmetric, nonerosive, and usually nondeforming. The arthritis frequently involves the proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints of the hands as well as the wrists and knees.
    • Consider avascular necrosis, which is common in patients who are taking glucocorticoids.
    • In addition, consider septic arthritis when one joint is inflamed out of proportion to all other joints.
  • Central nervous system findings
    • All types of seizures have been reported; the most frequent is the grand mal seizure. Sensory or sensorimotor neuropathies are also common.
    • Incidence of stroke is high in the first 5 years of disease. Patients with antiphospholipid antibodies are at higher risk for such events.
  • Funduscopic examination is important in patients with visual complaints. Retinal vasculitis can lead to blindness and is demonstrated by sheathed narrow retinal arterioles with white exudates adjacent to the vessels.
  • The renal system can be affected leading to renal failure. Specific signs and symptoms of renal disease may not be apparent until advanced nephrotic syndrome or renal failure is present; therefore, obtaining a urine analysis and serum BUN and creatinine levels on a regular basis is important.
  • Cardiovascular system findings
    • Atherosclerosis occurs prematurely in patients with SLE and is an independent risk factor for cardiovascular disease.
    • Pulmonary hypertension, vasculitis with digital infarcts, and splinter hemorrhages may be observed.
    • Systolic murmurs are reported in up to 70% of cases. They may be secondary to fever, hypoxia, anemia, or Libman-Sacks endocarditis (associated with antiphospholipid antibodies).
    • Pericarditis has an incidence of 20-30% and is the most common presentation of heart involvement. It is usually associated with small effusions, but it may involve larger effusions when uremia is concomitant. Myocarditis can cause heart failure, arrhythmias, and sudden death.
  • Pulmonary findings
    • Tachypnea, cough, and fever are common manifestations of lupus pneumonitis.
    • Hemoptysis may signify pulmonary hemorrhage secondary to the disease. However, infection is the most common cause of infiltrates seen on radiographs.

Causes

  • Many of the clinical manifestations of systemic lupus erythematosus (SLE) are caused by the effects of circulating immune complexes on various tissues or to the direct effects of antibodies to cell surface components.
  • Whether polyclonal B-cell activation or a response to specific antigens exists is unclear.
  • Cytotoxic T cells and suppressor T cells (which would normally downregulate immune responses) are decreased.
  • The generation of polyclonal T-cell cytolytic activity is impaired.
  • Helper (CD4+) T cells are increased.
  • A lack of immune tolerance is observed in animal models.
  • A high concordance rate (14-57%) of SLE is noted in monozygotic twins. Each patient manifests his or her disease differently.
  • Five to twelve percent of relatives of patients with SLE have the disease.
  • If a mother has SLE, her daughter's risk of developing the disease is 1:40, and her son's risk is 1:250.
  • Administration of estrogen to postmenopausal women appears to double the risk of developing SLE.
  • Breastfeeding is associated with a decreased risk of developing SLE.
  • Viruses, for example, may stimulate specific cells in the immune network. Patients with SLE also have higher titers of antibodies to Epstein-Barr virus (EBV), have increased circulating EBV viral loads, and make antibodies to retroviruses, including to protein regions homologous to nuclear antigens.
  • Trypanosomiasis or mycobacterial infections may induce anti-DNA antibodies or even lupuslike symptoms, and lupus flares may follow bacterial infections.
  • Silica dust and cigarette smoking may increase the risk of developing SLE.
  • Photosensitivity is clearly a precipitant of skin disease.
  • The presence of antiphospholipid antibodies causes physical signs of thrombosis.

More on Systemic Lupus Erythematosus

Overview: Systemic Lupus Erythematosus
Differential Diagnoses & Workup: Systemic Lupus Erythematosus
Treatment & Medication: Systemic Lupus Erythematosus
Follow-up: Systemic Lupus Erythematosus
Multimedia: Systemic Lupus Erythematosus
References
[ CLOSE WINDOW ]

References

  1. Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR. SLE--a disease of clearance deficiency?. Rheumatology (Oxford). Sep 2005;44(9):1101-7. [Medline].

  2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. Feb 28 2008;358(9):929-39. [Medline].

  3. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. Feb 17 2007;369(9561):587-96. [Medline].

  4. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. Jan 1999;42(1):46-50. [Medline].

  5. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18. [Medline].

  6. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. Jul 1995;22(7):1265-70. [Medline].

  7. Gladman DD, Urowitz MB. Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1333-53.

  8. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). May 1999;78(3):167-75. [Medline].

  9. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. Mar 1 1997;145(5):408-15. [Medline].

  10. Murali R, Jeyaseelan L, Rajaratnam S, John L, Ganesh A. Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India. Jul-Aug 1997;10(4):159-64. [Medline].

  11. Xie SK, Feng SF, Fu H. Long term follow-up of patients with systemic lupus erythematosus. J Dermatol. Jun 1998;25(6):367-73. [Medline].

  12. Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus. 1997;6(3):248-53. [Medline].

  13. Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care. Oct 2001;7(16 Suppl):S474-9. [Medline].

  14. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. Aug 2002;28(3):561-77, vi-vii. [Medline].

  15. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 250 cases. JAMA. Oct 12 1964;190:104-11. [Medline].

  16. Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore). Dec 1954;33(4):291-437. [Medline].

  17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Nov 1982;25(11):1271-7. [Medline].

  18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Sep 1997;40(9):1725. [Medline].

  19. Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, Brito-Zerón P, Bertolaccini L. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore). Nov 2008;87(6):311-8. [Medline].

  20. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol. Apr 2002;16(2):281-91. [Medline].

  21. Tierney, et al. Current Medical Diagnosis and Treatment. 2001:841-844.

  22. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. Mar 16 2009;9:11. [Medline].

  23. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. Mar 31 2001;357(9261):1027-32. [Medline].

  24. Amit M, Molad Y, Levy O, Wysenbeek AJ. Headache in systemic lupus erythematosus and its relation to other disease manifestations. Clin Exp Rheumatol. Jul-Aug 1999;17(4):467-70. [Medline].

  25. Braunwald E, Fauci AS, Kasper DL. Systemic Lupus Erythematosus. In: Harrison's Principles of Internal Medicine. 16th ed. 2005:1960-1967.

  26. Goldsmith L, Lazarus G, Tharp M. Adult and Pediatric Dermatology: A Color Atlas of Disease and Treatment. 1997.

  27. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. Oct 1 1996;125(7):549-57. [Medline].

  28. Hahn BH. Management of systemic lupus erythematosus. In: Textbook of Rheumatology. Vol 2. WB Saunders; 1997:1040-56.

  29. Hochberg MC, Silman AJ, Smolen JS, et al. Systemic lupus erythematosus. In: Practical Rheumatology. 3rd ed. 2004:417-437.

  30. Khoshbin S, Glanz BI, Schur PH. Neuropsychiatric syndromes in systemic lupus erythematosus: a new look. Clin Exp Rheumatol. Jul-Aug 1999;17(4):395-8. [Medline].

  31. Lahita RG. Clinical presentation of systemic lupus erythematosus. In: Textbook of Rheumatology. Vol 2. WB Saunders; 1997:1028-39.

  32. Marks R. Skin Diseases in Old People. 2nd ed. Martin Dunitz Ltd; 1999.

  33. Mills JA. Systemic lupus erythematosus. N Engl J Med. Jun 30 1994;330(26):1871-9. [Medline].

  34. Mochizuki T, Aotsuka S, Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med. Feb 1999;93(2):95-101. [Medline].

  35. Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. Mar 2001;77(905):157-65. [Medline].

  36. Molokhia M, Hoggart C, Patrick AL, Shriver M, Parra E, Ye J, et al. Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population. Hum Genet. Mar 2003;112(3):310-8. [Medline].

  37. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. Dec 18 2003;349(25):2399-406. [Medline].

  38. Stevenson FK, Natvig J. Autoantibodies revealed: the role of B cells in autoimmune disease. Immunol Today. Jul 1999;20(7):296-8. [Medline].

  39. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford). Mar 2000;39(3):238-44. [Medline].

  40. Wang CR, Chou CC, Hsieh KH, Chuang CY, Chen CY. Lupus patients with peripheral vascular thrombosis: the significance of measuring anticardiolipin antibody. Am J Emerg Med. Sep 1993;11(5):468-70. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Mark J Leber, MD, MPH, FACEP, Attending Physician and Faculty, Department of Emergency Medicine and Residency Program, Lincoln Medical and Mental Health Center
Mark J Leber, MD, MPH, FACEP is a member of the following medical societies: American College of Emergency Physicians and American College of Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Viraj S Lakdawala, MD, Resident Physician, Department of Emergency Medicine, Lincoln Medical and Mental Health Center, Bronx, NY
Viraj S Lakdawala, MD is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: Nothing to disclose.

Medical Editor

Richard S Krause, MD, Senior Faculty, Department of Emergency Medicine, State University of New York at Buffalo School of Medicine
Richard S Krause, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Gino A Farina, MD, Program Director, Associate Professor of Clinical Emergency Medicine, Department of Emergency Medicine, Long Island Jewish Medical Center, Albert Einstein College of Medicine
Gino A Farina, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.